Dr. Fuller Albright, in 1941, was the first to postulate the presence of a ‘substance’ that caused features of hyperparathyroidism in a cancer patient
2/
In this report, Dr. Albright essentially described the presence of PTH-like hormone in a cancer patient.
“I suspected that the tumor might be producing PTH. I therefore had it assayed but no PTH hormone was found”-Albright👇🏽 3/ nejm.org/doi/full/10.10…
You may recognize Fuller Albright’s name as he is also credited for describing the McCune-Albright Syndrome.
Here is the link to Fuller Albright’s biographical sketch pubmed.ncbi.nlm.nih.gov/21384213/ 4/
Albright’s report was published in 1941 but it wasn’t until 1980 that ⬆️ excretion of nephrogenous cyclic AMP was described as a marker of humorally-mediated hypercalcemia of malignancy
- that humoral factor turned out to be PTHrP pubmed.ncbi.nlm.nih.gov/6253785/ 5/
The protein was finally purified & sequenced using cell line from squamous cell carcinoma of the lung from a pt. with hypercalcemia of malignancy.
The protein had structural & functional similarities to PTH.
It was named PTHrP👇🏽
Time for a poll question:
-PTHrP mediated hypercalcemia of malignancy is due to:
⬆️ Bone resorption, ⬆️ renal distal tubular reabsorption of calcium and ⬆️ calcium absorption from the intestine
7/
PTHrP has several structural & functional similarities with PTH as both
⬆️ Bone resorption
⬆️ Renal distal tubular calcium reabsorption
⬇️ Renal proximal tubular phosphate reabsorption
8/
BUT unlike PTH, PTHrP is less likely to increase 1,25 vitamin D production so PTHrP does not increase intestinal calcium absorption
9/
In 1992, this publication in Lancet showed that PTHrP accounted for hypercalcemia of malignancy in up to 80% of cancer patients👇🏽
-PTHrP mediated hypercalcemia of malignancy is due to:
⬆️ Bone resorption, ⬆️ renal distal tubular reabsorption of calcium and ⬆️ calcium absorption from the intestine
11/
As the role of PTHrP in hypercalcemia of malignancy became more clear, the big question was does PTHrP have a physiological function?
The answer is yes
12/
PTHrP has paracrine actions in several tissues as shown in the figure below👇🏽
PTHrP likely plays an important role in fetal development & during lactation
It has been long known that fetal calcium levels are significantly higher than maternal calcium levels indicating an independent control of fetal calcium, and this effect was found to be independent of PTH👇🏽
Animal studies have shown that PTHrP stimulates placental calcium transfer to fetus which allows for mineralization of the fetal skeleton👇🏽
-In mice w/ PTHrP gene deletion fetal calcium is significantly lower than in mice w/ PTHrP pubmed.ncbi.nlm.nih.gov/18258656/ 15/
PTHrP is produced by the lactating mammary gland & it activates bone resorption to mobilize skeletal calcium stores
PTHrP likely plays a role in modulating calcium concentration in breast milk & lactation associated bone loss
⚡️Antibody (Ab) response to Pfizer vaccine in hemodialysis pts. has been reported, but the Ab response to Moderna vaccine in hemodialysis patients is not well known
Here we report Ab response to Moderna vaccine in patients on maintenance hemodialysis
2/
⚡️61 hemodialysis patients received the 2-dose Moderna vaccine series
-Of the 61 hemodialysis patients, 20 patients had prior h/o COVID-19
3/
⚡️It important for Nephrologists to be familiar with immune checkpoint inhibitor induced endocrinopathies as thyroid, pituitary & adrenal disorders can present with👇🏽
-Hyponatremia
-Hyperkalemia
-Metabolic acidosis
-Hypotension
2/
⚡️Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that target immune checkpoint proteins:
⚡️An important point to remember is that 98% of the potassium (K) stores in the body are intracellular so even a small amount of K released from the cells can significantly affect the concentration of ‘measured’ extracellular potassium
2/
⚡️When blood is drawn to measure potassium, you are measuring ‘extracellular’ potassium concentration and NOT intracellular potassium concentration
3/